Page 449 - Essential Haematology

Index / 435

chlorate poisoning 86 clinical features 192–3 factor IX defi ciency 349, 350,
cholecystectomy, hereditary diagnosis 192 352
spherocytosis 79 donor leucocyte infusions 310 haemophilia A 346, 347,
chorionic biopsy, haemophilia A genetic abnormalities 155 348–50, 351, 352
349 laboratory fi ndings 193, 195 hereditary 346, 347, 348–50,
Christmas disease see factor IX Ph chromosome 192, 193, 194 351, 352–4
defi ciency stem cell transplantation 198 liver disease 355
chromosomes treatment 195–6, 197, 198–9 massive transfusion syndrome
amplifi cation 158 protocols 164 340, 360
deletions 158 chronic myelomonocytic leukaemia thromboelastography 359, 360
duplications 158 192, 221 vitamin K defi ciency 354–6
nomenclature 156 chronic neutrophilic leukaemia see also disseminated intravascular
translocations 156, 157–8, 159, 192, 199 coagulation (DIC); von
160 ciclosporin, aplastic anaemia 293 Willebrand disease
chronic eosinophilic leukaemia circle of Willis, Doppler coagulation pathway 320, 321
192, 199 ultrasonography 419, 420 cobalamin see vitamin B 12
chronic granulomatous disease 116 circulatory overload, post- cold autoimmune haemolytic
chronic lymphocytic leukaemia transfusion 407–8 anaemias 82, 83, 84
(CLL) 151, 235–7, 238, clopidogrel collagen vascular diseases 370
239–41 defective platelet function 341–2 colon carcinoma 44
cytogenetics 237, 238, 239 venous thrombosis 378 colony-forming unit erythroid
disease course 241 Clostridium perfringens septicaemia (CFU E) 18
genetic abnormalities 155 86, 389, 390 colony-forming unit granulocyte,
immunophenotyping 236–7 clot retraction 325 erythroid, monocyte and
prognostic markers 237, 239 clotting factors 318, 320, 321, megakaryocyte
red cell aplasia 294 322, 323, 324 (CFU GEMM) 16
somatic hypermutation of Ig activated partial thromboplastin complement 133, 134
genes 237, 239 time 327, 328 compression paraplegia, multiple
staging 239 assays 328 myeloma 281
treatment 239–41 circulating antibodies 359–60 congenital dyserythropoietic
tumour cell phenotype 237, 239 diseases 331 anaemia 295–6
chronic lymphoid leukaemias inhibitors 325 congestive heart failure
235–43 coagulation 320, 322–4 anaemia 387
B-cell diseases 235–7, 238, abnormalities iron defi ciency 387
239–42 in malignancy 382–3, 384, 385 thalassaemia 54
diagnosis 235 in renal failure 387 connective tissue disorders 331
T-cell diseases 242–3 amplifi cation 323 haematological changes 385
chronic monocytic leukaemia 192 initiation 322–3 Coombs’ test see direct antiglobulin
chronic myeloid (myelogenous) neonates 418 test (DAT)
leukemia (CML) 192–9 physiological limitation 325, 326 core binding factor (CBF) 159
accelerated phase 198–9 pregnancy 414, 416 corticosteroids
acute transformation 198–9 screening tests 327–8 autoimmune neutropenia 120
atypical 221 in vivo 320, 322–3 autoimmune thrombocytopenic
BCR-ABL1 positive 192–3, 194, coagulation cascade 320 purpura 336
195–6, 197, 198–9 coagulation disorders 346–60 CLL 240
blastic transformation 198–9 acquired 354–60 red cell aplasia 294

chemotherapy 198 deficiencies caused by antibodies warm autoimmune haemolytic
chronic phase 195–6, 197, 198 359–60 anaemia 83